Wojciech Kozubski

ORCID: 0000-0003-2777-261X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Migraine and Headache Studies
  • Alzheimer's disease research and treatments
  • Multiple Sclerosis Research Studies
  • Neurological Disorders and Treatments
  • Peripheral Neuropathies and Disorders
  • Parkinson's Disease Mechanisms and Treatments
  • Acute Ischemic Stroke Management
  • Neurological disorders and treatments
  • Genetic Neurodegenerative Diseases
  • Autoimmune Neurological Disorders and Treatments
  • Folate and B Vitamins Research
  • Systemic Lupus Erythematosus Research
  • Sympathectomy and Hyperhidrosis Treatments
  • Cerebrovascular and Carotid Artery Diseases
  • Trigeminal Neuralgia and Treatments
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Atherosclerosis and Cardiovascular Diseases
  • Cardiovascular Health and Disease Prevention
  • Mitochondrial Function and Pathology
  • Ophthalmology and Eye Disorders
  • Cerebrovascular and genetic disorders
  • Dementia and Cognitive Impairment Research
  • Cancer Treatment and Pharmacology
  • Inflammatory Biomarkers in Disease Prognosis
  • Stroke Rehabilitation and Recovery

Poznan University of Medical Sciences
2016-2025

Polskie Towarzystwo Gastroenterologii
2019

Vrije Universiteit Amsterdam
2018

NeuroRx Research (Canada)
2018

University of Nottingham
2015

Queen's Medical Centre
2015

MorphoSys (Germany)
2015

University Hospital of Basel
2015

University School of Physical Education in Kraków
2015

Heliodor Swiecicki Clinical Hospital
2011

To determine the safety, pharmacokinetics (PK), and immunogenicity of recombinant human monoclonal antibody MOR103 to granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with multiple sclerosis (MS) clinical or MRI activity.In this 20-week, randomized, double-blind, placebo-controlled phase 1b dose-escalation trial (registration number NCT01517282), adults relapsing-remitting MS (RRMS) secondary progressive (SPMS) received an IV infusion placebo (n = 6) 0.5 8), 1.0 2.0 9)...

10.1212/nxi.0000000000000117 article EN cc-by-nc-nd Neurology Neuroimmunology & Neuroinflammation 2015-05-22

To describe global and domain-specific quality of life (QOL) after stroke to identify the factors that are important for post-stroke QOL.A hospital-based sample 72 patients was followed up 6 months onset. QOL assessed using Polish version Quality Life Index. Regression analysis performed variables best predicted QOL.The overall relatively good, although worse than subjects in a comparison group. The highest found 'Family' domain, lowest 'Health functioning' domain. Emotional support,...

10.1034/j.1600-0404.2003.02078.x article EN Acta Neurologica Scandinavica 2003-04-23

Parkinson's disease (PD) is one of the most common neurological diseases in elderly people. The mean age onset 55 years age, and risk for developing PD increases 5-fold by 70. In PD, there impairment both motor nonmotor (NMS) functions. strategy dysfunction treatment simple generally based on enhancement dopaminergic transmission means L-dihydroxyphenylalanine (L-dopa) dopamine (DA) agonists. L-dopa was discovered early -60's last century Hornykiewicz used patients with PD. related to...

10.2174/1389202914666131210213042 article EN Current Genomics 2014-03-08

Acute disseminated encephalomyelitis (ADEM) is a demyelinating disease, and there are some data that link this event with various vaccinations. We report young female admitted to the hospital headache, fever, back pain, nausea, vomiting, urinary retention. Two weeks prior, she received first dose of SARS-CoV-2 mRNA vaccine. Brain spinal cord magnetic resonance imaging (MRI) showed distinctive for ADEM widespread lesions. The patient was successfully treated methylprednisolone.

10.1002/acn3.51447 article EN cc-by-nc-nd Annals of Clinical and Translational Neurology 2021-09-04

Cognitive impairment occurs from the earliest stages of multiple sclerosis (MS) and progresses over time. The introduction disease modifying therapies (DMTs) has changed prognosis for MS patients, offering a potential opportunity improvement in cognitive arena as well.

10.5603/pjnns.97714 article EN other-oa Neurologia i Neurochirurgia Polska 2024-02-07

Although Parkinson's disease (PD) was first described almost 200 years ago, it remains an incurable with a cause that is not fully understood. Nowadays known disturbances in the structure of pathological proteins PD can be caused by more than environmental and genetic factors. Despite numerous debates controversies literature about role mutations SNCA PRKN genes pathogenesis PD, evident these play key maintaining dopamine (DA) neuronal homeostasis dysfunction this relevant to both familial...

10.2174/1389202914666131210205839 article EN Current Genomics 2014-02-01

Introduction: Despite the growing body of literature on consequences providing non-professional care to stroke survivors, determinants caregiving burden are still not fully recognized.Identification significant can facilitate caregiver intervention programs.The aim this study was evaluate level borne by caregivers patients and identify most important at 6 months after hospitalization.Material methods: Data were collected from 150 pairs patients/caregivers.Caregiver assessed Caregiver Burden...

10.5114/aoms.2014.46214 article EN cc-by-nc-sa Archives of Medical Science 2014-01-01

An elevated concentration of total homocysteine (tHcy) in plasma and cerebrospinal fluid is considered to be a risk factor for Alzheimer's disease (AD) Parkinson's (PD). Homocysteine (Hcy) levels are influenced by folate concentrations numerous genetic factors through the cycle, however, their role pathogenesis PD remains controversial. Hcy exerts neurotoxic action may participate mechanisms neurodegeneration, such as excitotoxicity, oxidative stress, calcium accumulation, apoptosis....

10.2174/1389202914666131210210559 article EN Current Genomics 2014-02-01

1. Stępień A, Kozubski W, Rożniecki JJ, Domitrz I. Migraine treatment recommendations developed by an Expert Group of the Polish Headache Society, Section Neurological and Pain Society. Neurol Neurochir Pol 2021; 55: 33–51. Google Scholar

10.5114/aoms/175063 article EN cc-by Archives of Medical Science 2024-02-09
Coming Soon ...